Precisely targeting the interface between
innate and adaptive immunity.
Home
Company
Management Team
Robert Mashal
Robert Schaub
Barbara Finck
Ron Goldstein
Board Of Directors
Robert Mashal
David Hung
Samuel Wu
Michael Ross
Scientific Advisory Board
Steve Balk
Peter Cresswell
Mark Exley
David Hafler
Peter Kiener
Mitchell Kronenberg
Alem Truneh
Brian Wilson
David Wofsy
Investors
SV Lifesciences
MedImmune Ventures
News
The appointment of Barbara Finck, M.D. to the position of chief medica
BIOWA and NKTT announce licensing of BIOWA's Potelligent® Technology
Selexis and nkt therapeutics enter into research services agreement.
NKT Therapeutics Broadens Scientific Advisory Board with Three New App
Contact Us
Robert Mashal
David Hung
Samuel Wu
MedImmune Ventures
Michael Ross
SV Life Sciences